WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H407426
CAS#: 1257994-15-2
Description: OXA-11 is a potent, novel small-molecule amino pyrimidine inhibitor (1.2 pM biochemical IC(50)) of focal adhesion kinase (FAK). OXA-11 inhibited FAK phosphorylation at phospho-tyrosine 397 with a mechanistic IC(50) of 1 nM in TOV21G tumor cells, which translated into functional suppression of proliferation in 3-dimensional culture with an EC(50) of 9 nM. Studies of OXA-11 activity in TOV21G tumor-cell xenografts in mice revealed a pharmacodynamic EC(50) of 1.8 nM, indicative of mechanistic inhibition of pFAK [Y397] in these tumors. OXA-11 slows tumor growth, potentiates the anti-tumor actions of cisplatin and--when combined with VEGFR-2 blockade--reduces metastasis of pancreatic neuroendocrine tumors in RIP-Tag2 mice.
Hodoodo Cat#: H407426
Name: OXA-11
CAS#: 1257994-15-2
Chemical Formula: C37H49F3N7O5P
Exact Mass: 759.35
Molecular Weight: 759.812
Elemental Analysis: C, 58.49; H, 6.50; F, 7.50; N, 12.90; O, 10.53; P, 4.08
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: OXA-11; OXA 11; OXA11.
IUPAC/Chemical Name: diethyl (3-methoxy-4-((4-((2-methyl-7-((1r,4r)-4-(4-methylpiperazin-1-yl)cyclohexyl)-3-oxoisoindolin-4-yl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzyl)phosphonate
InChi Key: HZOFIHCVZSUCBZ-DIVCQZSQSA-N
InChi Code: InChI=1S/C37H49F3N7O5P/c1-6-51-53(49,52-7-2)23-24-8-14-30(32(20-24)50-5)43-36-41-21-29(37(38,39)40)34(44-36)42-31-15-13-27(28-22-46(4)35(48)33(28)31)25-9-11-26(12-10-25)47-18-16-45(3)17-19-47/h8,13-15,20-21,25-26H,6-7,9-12,16-19,22-23H2,1-5H3,(H2,41,42,43,44)/t25-,26-
SMILES Code: COC1=CC(CP(OCC)(OCC)=O)=CC=C1NC2=NC(NC3=CC=C([C@@H]4CC[C@@H](N5CCN(C)CC5)CC4)C(CN6C)=C3C6=O)=C(C(F)(F)F)C=N2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 759.81 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Moen I, Gebre M, Alonso-Camino V, Chen D, Epstein D, McDonald DM. Anti-metastatic action of FAK inhibitor OXA-11 in combination with VEGFR-2 signaling blockade in pancreatic neuroendocrine tumors. Clin Exp Metastasis. 2015 Dec;32(8):799-817. doi: 10.1007/s10585-015-9752-z. PubMed PMID: 26445848; PubMed Central PMCID: PMC4651821.
2: Anjum MF, Lemma F, Cork DJ, Meunier D, Murphy N, North SE, Woodford N, Haines J, Randall LP. Isolation and detection of extended spectrum β-lactamase (ESBL)-producing enterobacteriaceae from meat using chromogenic agars and isothermal loop-mediated amplification (LAMP) assays. J Food Sci. 2013 Dec;78(12):M1892-8. doi: 10.1111/1750-3841.12297. PubMed PMID: 24329955.
3: Wang C, Cheng YQ. Thailandepsin a. Acta Crystallogr Sect E Struct Rep Online. 2011 Nov;67(Pt 11):o2948-9. doi: 10.1107/S1600536811041390. PubMed PMID: 22219976; PubMed Central PMCID: PMC3247358.
4: Yang D, Guo Y, Zhang Z. Combined porin loss and extended spectrum beta-lactamase production is associated with an increasing imipenem minimal inhibitory concentration in clinical Klebsiella pneumoniae strains. Curr Microbiol. 2009 Apr;58(4):366-70. doi: 10.1007/s00284-009-9364-4. PubMed PMID: 19219497.
5: Poirel L, Girlich D, Naas T, Nordmann P. OXA-28, an extended-spectrum variant of OXA-10 beta-lactamase from Pseudomonas aeruginosa and its plasmid- and integron-located gene. Antimicrob Agents Chemother. 2001 Feb;45(2):447-53. PubMed PMID: 11158739; PubMed Central PMCID: PMC90311.
6: Bou G, Oliver A, Martínez-Beltrán J. OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrob Agents Chemother. 2000 Jun;44(6):1556-61. Erratum in: Antimicrob Agents Chemother. 2006 Jun;50(6):2280. PubMed PMID: 10817708; PubMed Central PMCID: PMC89912.
7: Danel F, Hall LM, Duke B, Gur D, Livermore DM. OXA-17, a further extended-spectrum variant of OXA-10 beta-lactamase, isolated from Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1999 Jun;43(6):1362-6. PubMed PMID: 10348753; PubMed Central PMCID: PMC89279.
8: Danel F, Hall LM, Livermore DM. Laboratory mutants of OXA-10 beta-lactamase giving ceftazidime resistance in Pseudomonas aeruginosa. J Antimicrob Chemother. 1999 Mar;43(3):339-44. PubMed PMID: 10223588.
9: Danel F, Hall LM, Gur D, Livermore DM. OXA-16, a further extended-spectrum variant of OXA-10 beta-lactamase, from two Pseudomonas aeruginosa isolates. Antimicrob Agents Chemother. 1998 Dec;42(12):3117-22. PubMed PMID: 9835501; PubMed Central PMCID: PMC106009.
10: Danel F, Hall LM, Gur D, Livermore DM. OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1995 Aug;39(8):1881-4. PubMed PMID: 7486940; PubMed Central PMCID: PMC162847.
11: Scoulica E, Aransay A, Tselentis Y. Molecular characterization of the OXA-7 beta-lactamase gene. Antimicrob Agents Chemother. 1995 Jun;39(6):1379-82. PubMed PMID: 7574536; PubMed Central PMCID: PMC162747.
12: Philippon A, Arlet G, Lagrange PH. Origin and impact of plasmid-mediated extended-spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis. 1994;13 Suppl 1:S17-29. Review. PubMed PMID: 7821300.
13: Hall LM, Livermore DM, Gur D, Akova M, Akalin HE. OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1993 Aug;37(8):1637-44. PubMed PMID: 8215276; PubMed Central PMCID: PMC188033.
14: Fujimoto K, Oka T, Morimoto M. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152). Cancer Res. 1987 Mar 15;47(6):1516-22. PubMed PMID: 2434218.
15: Bregman MD, Meyskens FL Jr. In vitro modulation of human and murine melanoma growth by prostanoid analogues. Prostaglandins. 1983 Sep;26(3):449-56. PubMed PMID: 6581509.
16: Chrousos GP, Sauer MA, Loriaux DL, Cutler GB Jr. delta 1-11-oxa-11-deoxycortisol: a new antiglucocorticoid with activity in vivo. Steroids. 1982 Oct;40(4):425-31. PubMed PMID: 7170752.
17: Beck G, Bartmann W, Lerch U, Teufel H, Schölkens B. Antihypertensive activity of 16, 16-dimethyl-oxa-alkyl-prostaglandins of the PGA2, PGE2 and trans-delta 2-11-deoxy-PGE1 series: structure-activity relationships. Prostaglandins. 1980 Jul;20(1):153-69. PubMed PMID: 7403571.
18: Carroll FI, Hauser FM, Huffman RC, Coleman MC. Synthesis and biological evaluation of 10-oxa-11-deoxyprostaglandin E1 and 10-nor-9,11-secoprostaglandin F1 and their derivatives. J Med Chem. 1978 Apr;21(4):321-5. PubMed PMID: 650661.
